Viking Therapeutics, Inc. (VKTX)
Nasdaq · Healthcare · Biotechnology
$29.28−2.20%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.7B
- 52-week range
- $25.77 – $43.15
- 52-week change
- −7.25%
- EPS (trailing)
- −$4.67
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$360M
- Diluted EPS
- −$3.19
From the company’s annual report on SEC EDGAR.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 65 employees · vikingtherapeutics.com